ABEO - NASDAQ
Abeona Therapeutics Inc.
$5.82
+2.3%Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening rare genetic diseases. Its lead program is EB-101, an autologous, gene-corrected cell therapy that is in Phase III clinical trial for recessive dystrophic epidermolysis bullosa. The company also develops ABO-102, an adeno-associated virus (AAV)-based gene therapy for Sanfilippo syndrome type A; ABO-201 to treat CLN3 disease; ABO-401 for the treatment of cystic fibrosis; and ABO-50X for the treatment of genetic eye disorders. In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1974 and is headquartered in New York, New York.
At a Glance
Live SnapshotAbeona Therapeutics Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Operating losses indicate the core business is unprofitable. Requires restructuring or revenue growth.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Margin squeeze alert: Healthy gross margins but weak operating margins suggest excessive operating expenses. Cost optimization could unlock significant value.
Abeona Therapeutics Inc. Income Statement
ABEO • NASDAQ
| Abeona Therapeutics Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||||
5.8M | 0.0 | 3.5M | 1.4M | 3M | 10M | 0.0 | 3M | 837K | 889K | 1M | 925K | 2M | 4.4M | 1.8M | 481K | 352K | 291K | 57K | 0.0 | |
GROSS PROFIT | ||||||||||||||||||||
(1.5M) | (2.9M) | (1.6M) | (450K) | (0.0) | (0.0) | (8.7M) | (38.7M) | (17M) | (10.7M) | (0.0) | (0.0) | (125K) | (267K) | (1.2M) | (140K) | (0.0) | (0.0) | (0.0) | (0.0) | |
4.3M | -2.9M | 1.9M | 964K | 3M | 10M | -8.7M | -35.7M | -16.2M | -9.8M | 1M | 925K | 1.9M | 4.1M | 632K | 341K | 352K | 291K | 57K | 0.0 | |
OPERATING INCOME | ||||||||||||||||||||
(93.7M) | (61.3M) | (49M) | (51.9M) | (92.8M) | (91.4M) | (69.3M) | (61.2M) | (28.7M) | (24.8M) | (19.6M) | (4.1M) | (5.7M) | (8.5M) | (8.3M) | (7.9M) | (10M) | (17.2M) | (7M) | (4.9M) | |
(65M) | (29.9M) | (19M) | (17.3M) | (21.6M) | (23.8M) | (20.7M) | (20.1M) | (10.9M) | (13.3M) | (14.3M) | (3.7M) | (4.8M) | (6M) | (5.8M) | (4.5M) | (7.1M) | (4.3M) | (4.1M) | (2.8M) | |
(26.8M) | (34.4M) | (31.1M) | (29M) | (38.7M) | (30.1M) | (48.6M) | (38.7M) | (17M) | (10.7M) | (4.7M) | (333K) | (884K) | (2M) | (3.6M) | (3.3M) | (2.7M) | (12.6M) | (2.6M) | (2.1M) | |
-89.4M | -64.2M | -47.1M | -50.9M | -89.8M | -81.4M | -77.1M | -58.2M | -27.8M | -23.9M | -18.5M | -3.1M | -3.8M | -4.3M | -7.9M | -7.8M | -9.7M | -16.9M | -6.9M | -5.2M | |
PRE-TAX INCOME | ||||||||||||||||||||
(3.7M) | (4.2M) | (418K) | (736K) | (3.7M) | (4.1M) | (400K) | (11K) | (8K) | (6K) | (6K) | (582K) | (279K) | (608K) | (0.0) | (607K) | (539K) | (911K) | (3.5M) | (7.4M) | |
1.8M | 38K | 1.7M | -305K | -3.6M | -2.8M | 808K | 1.5M | 517K | 2M | 4M | -537K | -28K | -366K | 1.3M | 1.4M | -510K | -700K | -3.4M | 0.0 | |
(1.9M) | -2.9M | -1.1M | (5.7M) | (32.5M) | (37.5M) | (0.0) | (2.4M) | (741K) | (825K) | (551K) | (11K) | (3K) | (419K) | -1.1M | (0.0) | (259K) | (253K) | (279K) | (0.0) | |
160.7M | 477K | -7.1M | 11.2M | 4.9M | -2.8M | 808K | 1.5M | 517K | 2M | 4M | -23.6M | 8.3M | -6.2M | 5.4M | 220K | -7.2M | -300K | -15M | -8.2M | |
71.3M | -63.7M | -54.2M | -39.7M | -84.9M | -84.2M | -76.3M | -56.7M | -27.3M | -21.9M | -14.5M | -26.8M | 4.4M | -10.5M | -2.5M | -7.5M | -16.8M | -17.2M | -21.9M | -13.4M | |
NET INCOME | ||||||||||||||||||||
(100K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (400K) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (17K) | (0.0) | (7.7M) | (0.0) | -61K | -173K | |
71.2M | -63.7M | -54.2M | -39.7M | -84.9M | -84.2M | -76.3M | -56.7M | -27.3M | -21.9M | -14.5M | -26.8M | 4.4M | -10.5M | -2.5M | -7.5M | -17.3M | -31.4M | -21.7M | -12.9M |
SEC Filings
ABEO - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | June 04, 2026 | June 03, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 13, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | May 13, 2026 | May 13, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 07, 2026 | April 01, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 20, 2026 | March 16, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 17, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 17, 2026 | March 17, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 09, 2026 | March 09, 2026 | 2026 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your ABEO research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.